After having set up a R&D hub for the biomanufacturing of clinical trial supplies in Gdansk, Polpharma is expanding its European footprint with a €100m investment in Warsaw. Several take-overs previously made the company a one-stop shop for biomanufacturing. European Biotechnology spoke with Federico Pollano, Director Contract Manufacturing and Business Development at the CDMO and biosimilars maker, about Polpharma’s strategy and expansion of biologics production.
Newron raises CHF27m
Latest NewsNeurology specialist Newron Pharmaceuticals S.p.A. (Milan) has raised gross proceeds of CHF 27m through a private placement of new shares via an accelerated book-building process.
EU approves Roche’s atezolizumab for bladder cancer
Latest NewsThough not reaching the overall surival endpoint in Phase III, the European Commission has granted label extension for Roche’s checkpoint blocker Tecentriq in two types of metastatic bladder cancer.
Da Volterra bags €20m EIB investment
Latest NewsFrench microbiota specialist Da Volterra has received an EIB loan to speed up development of treatments that prevent antibiotic resistance and hospital acquired infections.
microRNA blocks life-threatening ARDS
Latest NewsA team of US and German researchers has found that neutrophils secrete a regulatory RNA into lung tissue that protects against harmful inflammations.
Vesalius Biocapital and IFD launch life sciences fund
Latest NewsHealthcare investor Vesalius Biocapital has created a new investment vehicle in collaboration with the Portuguese National Promotional bank (IFD) aimed at investing in Portuguese life science companies.
Immunocore nabs US$40m from Gates Foundation
Latest NewsBritish T cell receptor specialist Immunocore Ltd will receive a US$40m investment from the the Bill & Melinda Gates Foundation to develop immunotherapies that fight tuberculosis and HIV.
.
Polpharma: Making biologics economic
OpinionCHMP candidate check
Latest NewsThe European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) published the results of its September meeting.
EMA rejects Santhera’s DMD drug
Latest NewsThe European Medicine Agency’s CHMP has rejected a type II extension application to Santhera Pharmaceutical’s coenzyme Q10 analogon idebenone (Raxone) as treatment for patients with Duchenne muscular dystrophy (DMD). Raxone was approved under exceptional circucumstances in September 2015 to treat visual impairment in patients with the rare eye disease LHON.
Sophia Genetics raises US$30m
Latest NewsArtificial intelligence (AI) specialist Sophia Genetics SA (St. Sulpice, Switzerland) raised US$30m in a series D round to foster global expansion of its cancer diagnostics annotation platform SOPHiA AI.